Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model

The AKT/mammalian target of rapamycin (AKT/mTOR) and ERK MAPK signaling pathways have been shown to cooperate in prostate cancer progression and the transition to androgen-independent disease. We have now tested the effects of combinatorial inhibition of these pathways on prostate tumorigenicity by...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Kinkade, Carolyn Waugh, Castillo-Martin, Mireia, Puzio-Kuter, Anna, Yan, Jun, Foster, Thomas H., Gao, Hui, Sun, Yvonne, Ouyang, Xuesong, Gerald, William L., Cordon-Cardo, Carlos, Abate-Shen, Cory
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society for Clinical Investigation 2008
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC2518074/
https://ncbi.nlm.nih.gov/pubmed/18725989
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI34764
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg